Acceptance of the IND application enables Aridis to broaden and accelerate its current Phase 2a study of AR-301 as an adjunctive therapy with standard-of-care antibiotics in to the United States. The study is currently underway in three European countries, with further expansion in to the United Kingdom also planned. Top-line outcomes from the accelerated Phase 2a study are expected in the first fifty % of 2016. Related StoriesParatek initiates Omadacycline phase 3 clinical research in community acquired bacterial pneumonia One World Lab announces collaboration with BenchWise to improve antibody researchMcMaster research shows great things about corticosteroid therapy for patients with pneumoniaPaul-Andre de Lame, M.D., Chief Medical Officer of Aridis, stated, ‘We are looking towards expanding the Phase 2a trial of AR-301, our second most advanced product candidate, into the United States.Insurers providing medical trends for the survey cover a total of around 150 million people. In its 22nd National Health Care Trend Survey, Buck discovered costs are projected to increase at rates that are up somewhat from the tendencies reported in the prior two surveys, as shown in the next chart: The trend factors reported in our survey reflect, partly, that health insurers anticipate higher state costs under healthcare reform, stated Harvey Sobel, FSA, a Buck principal and consulting who directed the study actuary. Also, because of current financial uncertainty, insurers could be projecting higher claim costs because workers who stay after layoffs tend to be older and more costly to insure.